Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Retained Earnings (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Retained Earnings for 6 consecutive years, with $727000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 217.47% to $727000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $727000.0 through Dec 2025, up 217.47% year-over-year, with the annual reading at $727000.0 for FY2025, 217.47% up from the prior year.
  • Retained Earnings for Q4 2025 was $727000.0 at 4D Molecular Therapeutics, up from $671000.0 in the prior quarter.
  • The five-year high for Retained Earnings was $1.1 million in Q3 2024, with the low at -$678.8 million in Q2 2025.
  • Average Retained Earnings over 5 years is -$165.2 million, with a median of -$77.0 million recorded in 2021.
  • The sharpest move saw Retained Earnings plummeted 147130.77% in 2022, then skyrocketed 1331.25% in 2024.
  • Over 5 years, Retained Earnings stood at -$207.0 million in 2021, then plummeted by 51.93% to -$314.5 million in 2022, then skyrocketed by 100.01% to $16000.0 in 2023, then surged by 1331.25% to $229000.0 in 2024, then surged by 217.47% to $727000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $727000.0, $671000.0, and -$678.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.